Patent EP0201079A2 successfully refreshed from Google Patents.
EP0201079A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Delayed solid phase immunologic assay
Assignee: Nichols Institute Diagnostics
•
Filing: 1986-05-06
•
Granted: —
•
Expires: 2006-05-06
Abstract
Abstract A method for the determination of a substance present in a sample, which comprises: (a) contacting a sample containing a substance with: (i) a first immunological binding partner to the substance, wherein the first immunological binding partner is bound to biotin or a biotin-binding protein, (ii) a second immunological binding partner to the substance, wherein the second immunological binding partner is detectably labeled, and (iii) a biotin binding protein or biotin bound to a carrier; (b) incubating the components of step (a) for a period of time and under conditions sufficient to form an immune complex between the substance, the first immunological binding partner, the second immunological binding partner, and the carrier; (c) separating the carrier from the sample; and (d) determining the detectably labeled second immunological binding partner in either the sample or the carrier; wherein the reaction between the first immunological binding partner and the carrier occurs after, or substantially contemporaneously with, formation of an immune complex between the first immunological binding partner and the substance.
Inventors
- 👤 Richard Zahradnik
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 03:46
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/536; G01N33/537; G01N33/538; G01N33/543; G01N33/54353; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/975; Y10S436/00; Y10S436/815; Y10S436/817; Y10S436/824; Y10S530/00; Y10S530/862
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
170 words
A method for the determination of a substance present in a sample, which comprises: (a) contacting said sample containing said substance with: (i) a first immunological binding partner to said substance, said first immunological binding partner being bound to biotin or a biotin binding protein, (ii) a second immunological binding partner to said substance, said second immunological binding partner being detectably labeled, and (iii) a biotin binding protein or biotin bound to a carrier; (b) incubating the components of step (a) simultaneously or separately for a period of time and under conditions sufficient to form an immune complex between said substance, said first immunological binding partner, said second immunological binding partner, and the carrier; (c) separating said carrier from the sample; and (d) determining the detectably labeled second immunological binding partner in either the sample or the carrier; wherein the reaction between said first immunological binding partner and said carrier occurs after, or substantially contemporaneously with, formation of an immune complex between said first immunological binding partner and said substance.
Claim 2
Independent Claim
170 words
A method for the determination of a substance present in a sample, which comprises: (a) contacting said sample containing said substance with: (i) a first immunological binding partner to said substance, said first immunological binding partner being bound to biotin or a biotin binding protein, (ii) a second immunological binding partner to said substance, said second immunological binding partner being detectably labeled, and (iii) a biotin binding protein or biotin bound to a carrier; (b) incubating the components of step (a) simultaneously or separately for a period of time and under conditions sufficient to form an immune complex between said substance, said first immunological binding partner, said second immunological binding partner, and the carrier; (c) separating said carrier from the sample; and (d) determining the detectably labeled second immunological binding partner in either the sample or the carrier; wherein the reaction between said first immunological binding partner and said carrier occurs after, or substantially contemporaneously with, formation of an immune complex between said first immunological binding partner and said substance.
Claim 3
Dependent Claim
16 words
The method of claim 1 wherein said substance is exogenous to the source of said sample.
Claim 4
Dependent Claim
16 words
The method of claim 1 wherein said substance is endogenous to the source of said sample.
Claim 5
Dependent Claim
19 words
The method of claim 3 wherein said endogenous substance is a hormone, a steroid, a lipid or an enzyme.
Claim 6
Independent Claim
68 words
The method of any of claims 1 to 4 wherein said first immunological binding partner is one or more monoclonal antibodies and said second immunological binding partner is a region-specific polyclonal antibody, or wherein said first and second immunological binding partners are monoclonal antibodies produced by the same cell line, or wherein said first and second immunological binding partners are different monoclonal antibodies produced by different cell lines.
Claim 7
Dependent Claim
12 words
The method of claim 3 wherein said endogenous substance is an immunoglobulin.
Claim 8
Dependent Claim
53 words
'7. The method of claim 6 wherein said first immunological binding partner is a substance capable of being bound by said immunoglobulin and said second immunological binding partner is one or more monoclonal antibodies specific to the class of said immunoglobulin, or is a polyclonal antibody specific to the class of said immunoglobulin.
Claim 9
Dependent Claim
16 words
The method of claim 7 wherein said substance is an allergen and said immunoglobulin is IgE.
Claim 10
Dependent Claim
35 words
The method of claim 1 wherein said detectably labeled second immunological binding partner is labeled with an enzyme, with a radioactive isotope, with a fluorescent compound, with a chemiluminescent compound, or with a bioluminescent compound.
Claim 11
Independent Claim
112 words
A method of forming a region-specific polyclonal antibody to a biological substance capable of being bound by antibody and having at least two different epitopes, comprising the steps of: (a) binding said substance to a carrier via one or more monoclonal antibodies specific for an epitope(s) on said substance, said monoclonal antibody and said substance being firmly bound to said carrier; (b) binding a polyclonal antibody specific for said substance to said carrier bound substance; (c) washing said bound polyclonal antibody; (d) eluting said bound polyclonal antibody from said substance under conditions such that said monoclonal antibody and said substance remain bound to said carrier; and (e) recovering said region-specific polyclonal antibody.
Claim 12
Independent Claim
112 words
A method of forming a region-specific polyclonal antibody to a biological substance capable of being bound by antibody and having at least two different epitopes, comprising the steps of: (a) binding said substance to a carrier via one or more monoclonal antibodies specific for an epitope(s) on said substance, said monoclonal antibody and said substance being firmly bound to said carrier; (b) binding a polyclonal antibody specific for said substance to said carrier bound substance; (c) washing said bound polyclonal antibody; (d) eluting said bound polyclonal antibody from said substance under conditions such that said monoclonal antibody and said substance remain bound to said carrier; and (e) recovering said region-specific polyclonal antibody.
Claim 13
Dependent Claim
11 words
Compounds capable of inducing IgE production, said compounds being biotinylated. -
Claim 14
Dependent Claim
11 words
Compounds capable of inducing IgE production, said compounds being biotinylated. -
Claim 15
Dependent Claim
85 words
A kit useful for the detection of a substance in a sample comprising a carrier being compartmentalized to receive in close confinement therein one or more containers wherein (a) a first container contains an immunological binding partner to said substance said partner bound to biotin or a biotin-binding protein; (b) a second container contains an immunological binding partner to said substance said partner bound to a detectable label; and (c) a third container contains a carrier to which a biotin-binding protein or biotin is bound.
Claim 16
Dependent Claim
85 words
A kit useful for the detection of a substance in a sample comprising a carrier being compartmentalized to receive in close confinement therein one or more containers wherein (a) a first container contains an immunological binding partner to said substance said partner bound to biotin or a biotin-binding protein; (b) a second container contains an immunological binding partner to said substance said partner bound to a detectable label; and (c) a third container contains a carrier to which a biotin-binding protein or biotin is bound.
Claim 17
Dependent Claim
59 words
The kit of claim 12 wherein said first container contains a monoclonal antibody and said second container contains a region-specific polyclonal antibody, or wherein said first container and said second container both contain monoclonal antibodies produced by the same cell line or wherein said first container and said second container contain different monoclonal antibodies produced by different cell lines.
Claim 18
Dependent Claim
11 words
The kit of claim 12 wherein said substance is an immunoglobulin.
Claim 19
Dependent Claim
45 words
The kit of claim 14 wherein said first container contains a substance capable of being bound by said immunoglobulin and said second container contains a monoclonal antibody specific to the class of said immunoglobulin, or a polyclonal antibody specific for the class of said immunoglobulin.
Claim 20
Dependent Claim
17 words
The kit of claim 15 wherein said substance is an allergen and said immunoglobulin is IgE. r
Claim 21
Dependent Claim
85 words
A kit useful for the detection of a substance in a sample comprising a carrier being compartmentalized to receive in close confinement therein one or more containers wherein (a) a first container contains i) a first immunological binding partner to said substance said partner bound to biotin or a biotin-binding protein and ii) a second immunological binding partner to said substance said partner bound to a detectable label; and (b) a second container contains a carrier to which a biotin-binding protein or biotin is bound.
Claim 22
Dependent Claim
85 words
A kit useful for the detection of a substance in a sample comprising a carrier being compartmentalized to receive in close confinement therein one or more containers wherein (a) a first container contains i) a first immunological binding partner to said substance said partner bound to biotin or a biotin-binding protein and ii) a second immunological binding partner to said substance said partner bound to a detectable label; and (b) a second container contains a carrier to which a biotin-binding protein or biotin is bound.
Claim 23
Dependent Claim
47 words
The kit of claim 17 wherein said first container contains a monoclonal antibody and a region-specific polyclonal antibody , or wherein said first container contains monoclonal antibodies produced by the same cell line, or wherein said first container contains different monoclonal antibodies produced by different cell lines.
Claim 24
Dependent Claim
11 words
The kit of claim ,17 wherein said substance is an immunoglobulin.
Claim 25
Dependent Claim
42 words
The kit of claim 19 wherein said first container contains a substance capable of being bound by said immunoglobulin and a monoclonal antibody specific to the class of said immunoglobulin, or a polyclonal antibody specific for the class of said immunoglobulin .
Claim 26
Dependent Claim
17 words
The kit of claim 20 wherein said substance is an allergen and said immunoglobulin is IgE. 1
Claim 27
Dependent Claim
50 words
22 . A composition comprising a first immunological binding partner to a substance said partner bound to biotin or a biotin-binding protein, and a second immunological binding partner to said substance said partner bound to a detectable label, wherein said first and second immunological binding partners are in non-aqueous form.
Claim 28
Dependent Claim
50 words
22 . A composition comprising a first immunological binding partner to a substance said partner bound to biotin or a biotin-binding protein, and a second immunological binding partner to said substance said partner bound to a detectable label, wherein said first and second immunological binding partners are in non-aqueous form.
Claim 29
Dependent Claim
37 words
The composition of claim 22 which comprises a monoclonal antibody and a region-specific polyclonal antibody, or which comprises monoclonal antibodies produced by the same cell line, or which comprises different monoclonal antibodies produced by different cell lines.
Claim 30
Dependent Claim
82 words
A kit useful for the detection of hGH in a sample comprising a carrier being compartmentalized to receive in close confinement therein one or more containers wherein: (a) a first container contains avidin coated polystyrene beads; (b) a second container contains a first mouse monoclonal antibody detectably labeled with 125 1 and a second mouse monoclonal antibody bound to biotin, wherein said monoclonal antibodies react with different epitopes of hGH; and (c) a series of containers each containing increasing amounts of hGH.
Claim 31
Dependent Claim
82 words
A kit useful for the detection of hGH in a sample comprising a carrier being compartmentalized to receive in close confinement therein one or more containers wherein: (a) a first container contains avidin coated polystyrene beads; (b) a second container contains a first mouse monoclonal antibody detectably labeled with 125 1 and a second mouse monoclonal antibody bound to biotin, wherein said monoclonal antibodies react with different epitopes of hGH; and (c) a series of containers each containing increasing amounts of hGH.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.